News Nanexa AB

Equities

Delayed Nasdaq Stockholm Other stock markets 09:11:04 2024-04-29 EDT			5-day change	1st Jan Change
0.62 ^SEK	+2.31%		-3.12%	-49.59%

04-16	Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed	CI
03-08	Transcript : Nanexa AB - Special Call

Nanexa invites to Capital Markets Day on May 7	05:30am	AQ
Approval of clinical trial application for NEX-22 study delayed	04-16	AQ
Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed	04-16	CI
Notice of annual general meeting in Nanexa AB (publ)	04-15	AQ
Nanexa publishes annual report for 2023	03-27	AQ
Transcript : Nanexa AB - Special Call	03-07
Nanexa - NEX-22, partner projects, and Novo Nordisk evaluation prioritized	02-22	AQ
Equity Research \| NANEXA: Focus on dual GLP-1 opportunities and the partner projects	02-22	AQ
Nanexa publishes year-end report and Q4 report 2023	02-21	AQ
Nanexa AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-21	CI
Invitation to presentation of Nanexa's year-end report and Q4 report 2023	02-20	AQ
Equity Research \| NANEXA: Lining up to make Nanexa (close to) a pure GLP-1 play	12-21	AQ
Nanexa’s clinical trial application for NEX-22 Phase I study assessed by EMA	12-20	AQ
Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA	12-20	CI
Nanexa optimizes business operations through tactical priorities	12-20	AQ
Nanexa changes Certified Adviser to Carnegie Investment Bank AB (publ)	11-30	AQ
Nanexa Signs Feasibility Study Contract for PharmaShell; Shares Jump	11-29	MT
Nanexa signs evaluation agreement with a large global pharmaceutical company	11-29	AQ
Nanexa Q3 - Focused approach	11-21	AQ
Equity Research \| NANEXA: Raising our LOAs following a review of the projects	11-21	AQ

No results for this search